Index S&P 500
P/E 24.63
EPS (ttm) 9.21
Insider Own 2.03%
Shs Outstand 51.34M
Perf Week -6.03%
Market Cap 11.65B
Forward P/E 18.23
EPS next Y 12.44
Insider Trans -3.04%
Shs Float 50.31M
Perf Month -15.43%
Income 474.62M
PEG 2.68
EPS next Q 2.06
Inst Own 101.31%
Short Float 3.15%
Perf Quarter 6.96%
Sales 4.13B
P/S 2.82
EPS this Y 3.35%
Inst Trans 3.21%
Short Ratio 2.94
Perf Half Y 22.48%
Book/sh 70.06
P/B 3.24
EPS next Y 12.82%
ROA 6.01%
Short Interest 1.58M
Perf Year 11.79%
Cash/sh 5.50
P/C 41.21
EPS next 5Y 9.19%
ROE 14.44%
52W Range 161.65 - 275.00
Perf YTD -4.07%
Dividend Est. -
P/FCF 31.87
EPS past 5Y 14.84%
ROI 7.12%
52W High -17.53%
Beta 1.44
Dividend TTM -
Quick Ratio 1.16
Sales past 5Y 12.89%
Gross Margin 33.56%
52W Low 40.29%
ATR (14) 6.82
Dividend Ex-Date -
Current Ratio 1.52
EPS Y/Y TTM -3.17%
Oper. Margin 15.82%
RSI (14) 26.53
Volatility 2.99% 2.47%
Employees 21800
Debt/Eq 0.87
Sales Y/Y TTM 3.86%
Profit Margin 11.49%
Recom 1.94
Target Price 271.56
Option/Short Yes / Yes
LT Debt/Eq 0.85
EPS Q/Q -0.65%
Payout 0.00%
Rel Volume 0.76
Prev Close 227.55
Sales Surprise 2.24%
EPS Surprise 2.42%
Sales Q/Q -7.85%
Earnings May 09 BMO
Avg Volume 538.99K
Price 226.78
SMA20 -10.79%
SMA50 -10.03%
SMA200 5.12%
Trades
Volume 409,077
Change -0.34%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Downgrade
Guggenheim
Buy → Neutral
Sep-13-23 Initiated
TD Cowen
Market Perform
$212
Jul-10-23 Downgrade
Citigroup
Buy → Neutral
$260 → $225
Feb-23-23 Upgrade
Guggenheim
Neutral → Buy
$255
Jan-12-23 Downgrade
Jefferies
Buy → Hold
Sep-30-22 Upgrade
Jefferies
Hold → Buy
$240
Aug-25-22 Initiated
Credit Suisse
Outperform
$285
Aug-04-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$350 → $250
May-24-22 Initiated
Guggenheim
Neutral
Apr-25-22 Downgrade
Jefferies
Buy → Hold
$370 → $280
Apr-07-22 Initiated
Stephens
Overweight
$377
Feb-17-22 Upgrade
Citigroup
Neutral → Buy
$400
Feb-17-22 Reiterated
UBS
Buy
$465 → $420
Feb-17-22 Reiterated
Morgan Stanley
Overweight
$465 → $430
Feb-17-22 Reiterated
Deutsche Bank
Buy
$409 → $350
Feb-17-22 Reiterated
BofA Securities
Buy
$445 → $400
Aug-05-21 Resumed
Credit Suisse
Neutral
$385
Dec-16-20 Downgrade
Citigroup
Buy → Neutral
$270 → $250
Sep-10-20 Upgrade
Jefferies
Hold → Buy
$254
Jul-01-20 Upgrade
BofA Securities
Neutral → Buy
$192
Show Previous Ratings
Apr-18-24 12:09PM
Apr-16-24 11:50AM
08:00AM
Apr-12-24 08:00AM
Apr-11-24 09:10AM
08:00AM
Loading…
08:00AM
Apr-09-24 08:00AM
Apr-04-24 08:00AM
Apr-01-24 08:00AM
Mar-27-24 08:00AM
Mar-26-24 09:39AM
Mar-23-24 09:00AM
(The Wall Street Journal)
Mar-21-24 08:00AM
Mar-15-24 11:30AM
10:30AM
09:46AM
Loading…
Mar-14-24 09:46AM
08:00AM
Mar-12-24 08:00AM
12:11AM
Mar-07-24 12:27PM
Mar-01-24 11:32PM
Feb-29-24 02:00AM
Feb-26-24 08:41AM
Feb-21-24 10:40AM
08:00AM
Feb-20-24 01:15PM
08:08AM
Feb-15-24 01:00PM
10:54AM
12:38AM
08:06PM
Loading…
Feb-14-24 08:06PM
(Morningstar Research) +11.30%
09:30AM
09:30AM
08:09AM
07:19AM
(Associated Press Finance)
07:00AM
Feb-13-24 08:20AM
Feb-09-24 09:15AM
Feb-01-24 10:08AM
Jan-29-24 08:00AM
Jan-27-24 09:00AM
Jan-24-24 04:30PM
Jan-23-24 04:30PM
Jan-18-24 09:10AM
Jan-16-24 08:00AM
(Investor's Business Daily)
08:00AM
Jan-12-24 02:02PM
09:00AM
Jan-08-24 08:00AM
Jan-02-24 09:00AM
(The Wall Street Journal)
Dec-19-23 08:01AM
Dec-18-23 08:00AM
Dec-13-23 08:29AM
Dec-12-23 08:00AM
Dec-08-23 11:30AM
Dec-07-23 01:53PM
Dec-05-23 07:29AM
Dec-02-23 01:05AM
Nov-29-23 07:57AM
Nov-28-23 08:00AM
Nov-27-23 08:30AM
Nov-22-23 03:04AM
Nov-20-23 08:34PM
Nov-17-23 06:45PM
08:40AM
Nov-16-23 12:59PM
08:00AM
Nov-13-23 09:04AM
Nov-10-23 12:11PM
Nov-09-23 05:14PM
08:00AM
01:33AM
(Thomson Reuters StreetEvents)
Nov-08-23 03:20PM
10:59AM
09:30AM
08:54AM
08:26AM
07:06AM
(Associated Press Finance)
07:00AM
Nov-06-23 10:27AM
Nov-01-23 10:01AM
09:13AM
Oct-25-23 08:06PM
(Morningstar Research) -5.97%
Oct-24-23 12:10PM
Oct-23-23 10:10AM
Oct-19-23 08:00AM
Oct-16-23 08:30AM
08:00AM
Oct-11-23 08:00AM
Oct-10-23 09:10AM
Oct-05-23 12:55PM
Oct-02-23 11:35AM
Sep-27-23 12:04PM
Sep-26-23 08:02AM
08:00AM
Sep-25-23 11:40AM
08:00AM
Sep-21-23 11:36AM
Sep-20-23 08:30AM
Sep-18-23 12:03PM
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Knell Michael Gunnar CSVP&Chief Accounting Officer Mar 08 '24 Sale 267.52 808 216,156 7,024 Mar 11 04:42 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Mar 04 '24 Sale 261.05 2,750 717,890 7,832 Mar 05 04:54 PM Creamer Victoria L EVP & Chief People Officer Feb 29 '24 Sale 253.70 5,000 1,268,500 13,550 Mar 01 05:37 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 29 '24 Sale 253.45 3,786 959,545 4,792 Mar 04 04:09 PM Barbo William D Corporate Executive VP & CCO Feb 22 '24 Sale 248.50 4,050 1,006,425 22,879 Feb 23 04:57 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 15 '24 Option Exercise 144.67 5,882 850,949 8,478 Feb 20 05:32 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 15 '24 Sale 241.20 5,882 1,418,767 2,596 Feb 20 05:32 PM LaPlume Joseph W EVP, Corp Strategy & Develop Feb 15 '24 Sale 238.93 838 200,223 24,620 Feb 20 05:20 PM FOSTER JAMES C Chairman, President and CEO Jan 29 '24 Option Exercise 144.67 17,436 2,522,466 227,827 Jan 31 04:59 PM Girshick Birgit Corporate Executive VP & COO Jan 10 '24 Option Exercise 215.19 5,916 1,273,064 50,365 Jan 11 04:09 PM Creamer Victoria L EVP & Chief People Officer Dec 14 '23 Option Exercise 136.70 5,526 755,388 22,032 Dec 18 04:07 PM Creamer Victoria L EVP & Chief People Officer Dec 14 '23 Sale 225.00 5,526 1,243,350 16,506 Dec 18 04:07 PM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 30 '23 Sale 197.73 1,850 365,800 23,133 Dec 01 04:10 PM Girshick Birgit Corporate Executive VP & COO Nov 20 '23 Buy 187.82 1,322 248,298 44,449 Nov 21 05:07 PM FOSTER JAMES C Chairman, President and CEO Nov 14 '23 Buy 178.05 5,620 1,000,641 202,643 Nov 15 09:23 AM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 09 '23 Option Exercise 144.67 9,128 1,320,548 34,111 Nov 13 04:12 PM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 09 '23 Sale 173.48 9,128 1,583,522 24,983 Nov 13 04:12 PM WALLMAN RICHARD F Director Aug 24 '23 Buy 198.79 1,000 198,786 1,000 Aug 29 04:23 PM Barbo William D Corporate Executive VP & CCO Aug 10 '23 Option Exercise 144.67 5,511 797,276 9,103 Aug 14 04:17 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Aug 10 '23 Option Exercise 144.67 1,471 212,810 11,411 Aug 14 04:15 PM Barbo William D Corporate Executive VP & CCO Aug 10 '23 Sale 217.24 5,763 1,251,954 3,592 Aug 14 04:17 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Aug 10 '23 Sale 216.54 1,471 318,530 9,940 Aug 14 04:15 PM LaPlume Joseph W EVP, Corp Strategy & Develop Aug 10 '23 Sale 216.52 700 151,564 24,983 Aug 14 04:11 PM LaPlume Joseph W EVP, Corp Strategy & Develop May 15 '23 Sale 190.39 345 65,685 24,026 May 16 02:18 PM LaPlume Joseph W EVP, Corp Strategy & Develop May 12 '23 Sale 193.03 959 185,116 24,371 May 15 02:49 PM MASSARO GEORGE Director May 11 '23 Sale 193.43 288 55,708 4,964 May 15 02:42 PM
Index -
P/E -
EPS (ttm) -2.50
Insider Own 0.97%
Shs Outstand 492.85M
Perf Week -9.76%
Market Cap 6.38B
Forward P/E 12.21
EPS next Y 1.06
Insider Trans 0.80%
Shs Float 488.17M
Perf Month -19.96%
Income -1231.00M
PEG -
EPS next Q 0.26
Inst Own 98.35%
Short Float 2.55%
Perf Quarter -11.30%
Sales 4.42B
P/S 1.45
EPS this Y 3.44%
Inst Trans -3.02%
Short Ratio 3.02
Perf Half Y 35.74%
Book/sh 12.63
P/B 1.03
EPS next Y 15.16%
ROA -8.25%
Short Interest 12.47M
Perf Year 36.89%
Cash/sh 0.71
P/C 18.14
EPS next 5Y 8.87%
ROE -18.22%
52W Range 7.88 - 16.88
Perf YTD -13.09%
Dividend Est. -
P/FCF 48.73
EPS past 5Y -
ROI -10.20%
52W High -23.28%
Beta 1.33
Dividend TTM -
Quick Ratio 1.35
Sales past 5Y 9.00%
Gross Margin 43.88%
52W Low 64.34%
ATR (14) 0.47
Dividend Ex-Date -
Current Ratio 2.75
EPS Y/Y TTM -1484.90%
Oper. Margin 7.38%
RSI (14) 20.21
Volatility 4.10% 2.82%
Employees 9800
Debt/Eq 0.95
Sales Y/Y TTM -0.02%
Profit Margin -27.87%
Recom 2.00
Target Price 17.75
Option/Short Yes / Yes
LT Debt/Eq 0.94
EPS Q/Q -158.91%
Payout -
Rel Volume 1.39
Prev Close 13.57
Sales Surprise 3.33%
EPS Surprise -23.44%
Sales Q/Q 4.76%
Earnings May 08 BMO
Avg Volume 4.13M
Price 12.95
SMA20 -14.66%
SMA50 -17.50%
SMA200 -0.23%
Trades
Volume 5,739,868
Change -4.57%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-05-24 Upgrade
Stifel
Hold → Buy
$13 → $20
Dec-19-23 Initiated
Jefferies
Buy
$17
Dec-15-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$16
Dec-07-23 Initiated
Exane BNP Paribas
Outperform
$18
Apr-20-23 Upgrade
Barclays
Equal Weight → Overweight
$14
Aug-18-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$37 → $22
Aug-16-22 Downgrade
JP Morgan
Overweight → Neutral
$28 → $24
Jul-21-22 Downgrade
Goldman
Buy → Sell
$32 → $19
Jul-12-22 Initiated
Piper Sandler
Neutral
$22
Nov-18-21 Initiated
Morgan Stanley
Overweight
$40
Oct-28-21 Downgrade
Stifel
Buy → Hold
$37 → $34
Aug-05-21 Resumed
Credit Suisse
Outperform
$38
Jun-15-21 Upgrade
Cleveland Research
Underperform → Neutral
May-11-21 Upgrade
Gabelli & Co
Hold → Buy
May-11-21 Upgrade
Barclays
Underweight → Equal Weight
$25 → $29
Apr-15-21 Initiated
Stifel
Buy
$37
Mar-22-21 Downgrade
Gabelli & Co
Buy → Hold
Feb-26-21 Upgrade
Credit Suisse
Neutral → Outperform
$33 → $38
Dec-09-20 Downgrade
Argus
Buy → Hold
Nov-09-20 Downgrade
Barclays
Overweight → Underweight
$35 → $25
Show Previous Ratings
Apr-17-24 08:00AM
Apr-01-24 07:00AM
06:39AM
06:30AM
Mar-31-24 11:37PM
02:21PM
Loading…
Mar-13-24 02:21PM
Mar-12-24 07:00PM
Mar-05-24 10:15AM
Mar-04-24 08:33AM
Feb-29-24 03:30PM
01:08PM
08:00AM
07:03AM
Feb-28-24 10:58AM
Feb-26-24 11:41PM
(Thomson Reuters StreetEvents)
02:15PM
Loading…
02:15PM
09:30AM
06:52AM
06:27AM
Feb-22-24 08:00AM
Feb-21-24 09:15AM
Feb-19-24 10:00AM
Feb-15-24 07:00AM
Feb-13-24 01:09PM
Feb-09-24 10:15AM
Feb-08-24 02:46PM
08:00AM
Feb-07-24 01:25PM
Feb-05-24 07:01AM
(The Wall Street Journal) +7.94%
06:48AM
06:36AM
Loading…
06:36AM
06:33AM
06:33AM
Jan-18-24 08:22PM
Jan-17-24 08:30AM
Jan-08-24 07:35AM
Jan-02-24 08:33AM
Jan-01-24 09:15AM
Dec-19-23 08:00AM
Dec-14-23 05:08PM
Dec-08-23 09:00AM
Dec-07-23 04:37PM
Nov-27-23 08:00AM
Nov-10-23 05:20PM
Nov-09-23 03:49AM
Nov-08-23 04:03PM
12:21AM
(Thomson Reuters StreetEvents)
Nov-07-23 01:45PM
09:30AM
07:31AM
07:03AM
06:33AM
Nov-02-23 11:33AM
08:00AM
07:16AM
Nov-01-23 09:00AM
Oct-30-23 04:32PM
Oct-17-23 04:57PM
08:00AM
Oct-09-23 09:55AM
Oct-06-23 12:05PM
08:36AM
Oct-05-23 11:22AM
Oct-04-23 06:30AM
Sep-19-23 06:20AM
04:23AM
Sep-12-23 06:40AM
Sep-07-23 04:15PM
Sep-05-23 05:00PM
Aug-09-23 10:36AM
07:56AM
Aug-08-23 12:16AM
(Thomson Reuters StreetEvents)
Aug-07-23 02:30PM
12:34PM
09:30AM
07:50AM
06:33AM
Aug-02-23 07:10AM
06:55AM
Market Digest: CCI, CCI, ASH, ITW, MAR, MDC, SHEL, SANM, LEA, ANET, ELAN
(Argus Research)
Jul-20-23 08:00AM
Jul-18-23 08:00AM
Jul-17-23 08:48AM
Jul-14-23 06:29PM
12:21PM
Jul-13-23 06:30PM
05:24PM
Jul-01-23 09:21AM
Jun-24-23 03:19PM
Jun-05-23 08:00AM
May-30-23 06:20PM
May-25-23 08:00AM
May-16-23 11:13AM
May-09-23 06:30PM
11:25AM
07:55AM
06:34AM
May-08-23 05:45PM
May-04-23 10:00AM
May-03-23 01:58PM
01:43PM
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DOYLE WILLIAM F Director Mar 08 '24 Buy 16.30 15,000 244,500 61,330 Mar 12 04:32 PM Harrington Michael J Director Mar 08 '24 Buy 16.29 3,100 50,494 77,594 Mar 12 04:30 PM HOOVER R DAVID Director Mar 06 '24 Buy 16.14 20,000 322,808 185,000 Mar 08 05:09 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite